Cancers 2011, 3(4), 3838-3855; doi:10.3390/cancers3043838

Targeted Radionuclide Therapy

Department of Diagnostic Radiology, School of Medicine, Yale University, 333 Cedar St., New Haven, CT 06520, USA
* Author to whom correspondence should be addressed.
Received: 22 August 2011; in revised form: 27 September 2011 / Accepted: 27 September 2011 / Published: 11 October 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
PDF Full-text Download PDF Full-Text [289 KB, uploaded 11 October 2011 18:00 CEST]
Abstract: Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.
Keywords: targeted radiotherapy; radionuclide; radioimmunotherapy

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ersahin, D.; Doddamane, I.; Cheng, D. Targeted Radionuclide Therapy. Cancers 2011, 3, 3838-3855.

AMA Style

Ersahin D, Doddamane I, Cheng D. Targeted Radionuclide Therapy. Cancers. 2011; 3(4):3838-3855.

Chicago/Turabian Style

Ersahin, Devrim; Doddamane, Indukala; Cheng, David. 2011. "Targeted Radionuclide Therapy." Cancers 3, no. 4: 3838-3855.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert